ABSTRACT-We studied [3H]glutamate binding to human brain membrane preparations. We found that the binding assay of [3H]glutamate should be done at 4°C using glass-fiber filters pretreated with polyethyleneimine, sterile incubation buffer, and membrane preparations pretreated with a detergent. Under these assay conditions, we have characterized the three subtypes of glutamate receptors: N-methyl-D-aspartate-, quisqualate-and kainate-sensitive binding sites. Scatchard analysis revealed that the N-methyl-D-aspartate-sensitive [3H]glutamate binding sites consisted of a single component with a dissociation constant (Kd) of 28.2 ± 2.8 nM and total concentration (Bmax) of 36.2 ± 3.6 fmol/mg protein (N = 8). These data were much different from those presented in previous studies.
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L-Glutamate (GLU) is a candidate of major excitatory neurotransmitters in the mammalian central nervous system. From ligand binding experiments, glutamate binding sites in the brain are now divided into three subtypes according to differential affinities to exogenous agonists: N-methyl-D-aspartate (NMDA)-, quisqualate (QA)-and kainate (KA)-sensitive binding sites. [3H] glutamate is a useful ligand because it is able to interact with all three subtypes of the acidic amino acid receptors. However, there have been inconsistencies and lack of reproducibility in experiments using [3H] glutamate as a ligand (1) (2) (3) (4) . Recently, Ogita and Yoneda (5, 6) pointed out methodological artifacts and problems in the [3H] glutamate receptor binding assay and showed an apparent dissociation constant of 70 nM, which is more than ten-fold lower than the values obtained from the previous reports in rat brain preparations (1-4) by using their improved method.
The binding characteristics to human postmortem brain membrane preparations are also controversial and inconclusive (7, 8) . Apparent dissociation constant values of 844 nM to 1520 nM to [3H] glutamate binding in the human temporal cortical membrane preparation have been reported (7) , and these are more than ten-to twenty-fold higher than the value obtained from rat brain preparations by Ogita and Yoneda (5, 6) .
We decided to find the best assay conditions for [3H] 
MATERIALS AND METHODS

Autopsy materials
Brain tissues were obtained at autopsy from eight subjects (mean age, 78 years; mean postmortem delay, 8 hours) with no clinical or morphological evidence of brain pathology. None of them had been treated with neuroleptics or antidepressants. The causes of death were cardiac insufficiency or a terminal respiratory condition. Immediately after autopsy, the brains were divided into halves sagittally; one half was used in the biochemical binding assays and the other half was examined histopathologically. The half to be used for the biochemical binding assays was stored at -80°C until thawing for homogenization and the binding assay. Sixteen hours prior to dissection, the frozen brains were transferred to a -20°C cold box to allow sections to be easily and uniformly cut. They were cut coronally by a meat slicer in a 4°C room into approximately 3-mm-thick slices. The brain region was punched out from successive frozen slices using precooled needles. All brains appeared normal on histological examination. The brain region examined was the frontal cortex (Brodmann area 10).
Membrane preparations
The tissue samples were homogenized in 10 vol. of 50 mM Tris-acetate buffer (pH 7.4) using a Teflon-glass Potter-Elvejhem homogenizer (700 rpm, 10 strokes), and the homogenate was centrifuged at 1,000 X g for 10 min. The supernatant was collected and centrifuged at 50,000 X g for 20 min. The obtained pellet was resuspended in 30 vol. of 50 mM Tris-acetate buffer (pH 7.4), and stored at -20°C for more than 18 hours . On the day of the experiment, after thawing at room temperature, the membrane suspension was incubated either in the presence or absence of 0.08% Triton X-100 at 37°C for 30 min according to the method of Ogita and Yoneda (5) with a slight modification. After incubation, the suspension was centrifuged at 50,000 X g for 20 min, and the pellet was washed three times by resuspension in the buffer, followed by centrifugation. The final pellet was resuspended in the buffer and stored at -80°C. Protein concentrations of the membrane preparations were determined by the method of Lowry et al. (9) .
Binding assays
The membrane preparations (containing 100 ,ug protein) were incubated with [3H]-glutamate in 50 mM Tris-acetate buffer (pH 7.4) in a final volume of 250 ,ul at 4°C for 30 min. The reaction was terminated by adding 3 ml of ice-cold buffer and filtered under reduced pressure through Whatman GF/C glass-fiber filters which were presoaked in 0. 1% PEI for at least 5 hours according to the method of Bruns et al. (10) with a slight modification. The filters were washed three times with 3 ml ice-cold buffer and counted for radioactivity in 5 ml of scintillation fluid at the counting efficiency of 51-54%. Before each experiment, the buffer solution used for the incubation was boiled at 100°C and then filtered through a millipore filter (Millex-GV 0.22,um). Specific binding was calculated as the difference of the bindings in the absence and presence of 100 ,u M GLU (GLU-sensitive binding sites), 100 ,uM NMDA (NMDA-sensitive binding sites), 100,uM QA (QA-sensitive binding sites) or 100,uM KA (KA-sensitive binding sites).
Drugs used
[3H]Glutamate (specific activity, 54.7 Ci/ mmols) was purchased from New England Nuclear (Boston, MA, U.S.A.). N-methyl-Daspartate (NMDA), quisqualate (QA), DL-2-amino-5-phosphonovaleric acid (APV) and DL-2-amino-4-phosphonobutyric acid (APB) were purchased from Sigma Chemical Co. (St. Louis, MO, U.S.A.). Glutamate (GLU) and kainate (KA) were purchased from Nacalai Tesque (Kyoto, Japan). All other chemicals were of reagent grade or of the purest grade commercially available.
RESULTS
Here, we will report the significance of five factors. 1) The purity of [3H] [3H] glutamate were apparently more stable when the incubation buffer had been boiled and then filtered through a millipore filter before use (Fig. 1). 4 ) Treatment of the membrane preparations with a detergent: We obtained no substantial [3H] glutamate binding to untreated brain membrane preparations. The binding to membrane preparations pretreated with 0.08% Triton X-100 for 30 min was saturable and allowed us to assess the binding parameters (data not shown). 5) The reaction temperature: The binding was more stable under the incubation temperature of 4°C than 37°C (data not shown).
From the data presented above, we concluded that the binding assay of [3H] glutamate should be performed at 4°C, using glass-fiber filters treated with PEI, sterilized incubation buffer and membrane preparations pretreated with a detergent.
Under these assay conditions, [3H] glutamate binding was dose-dependently inhibited by exogenous glutamate analogues including APV and APB. The efficiency for the inhibition of the binding was in the order of GLU > QA > KA > NMDA = APV > APB (Fig. 2) . Specific [3H] glutamate binding reached an equilibrium within 15 min at 4°C. These bindings were reversible and Scatchard analysis of saturation isotherms revealed that GLU-, QA-, KA-or NMDA-sensitive [3H]glutamate binding was saturable and that each of them consisted of a single component (Fig. 3, Table 1 ).
In the case of NMDA-sensitive [3H] glutamate binding, the rate constant of association (K+t) was 2.133 X 106 M-1 min -1 , and the rate constant of dissociation (K-1) was 0.0673 min'. The dissociation constant calculated from the equation Kd = K1/K+ 1 was 31.6 nM, which agreed well with that estimated from Scatchard analysis.
DISCUSSION
The binding parameters obtained from Scatchard analysis were much different from those presented in the previous study. The Kd value was 1/20 and the Bmax value was 1/500 the values reported by Cross et al. (8) ; and the Kd value was 1/30 and the Bmax value was 1/20 the values reported by Cowburn et al. (7) . There may be several reasons for the discrepancies in the results of glutamate binding by different laboratories. Our present result suggests that differences in assay conditions and buffers may produce different results. In addition, Bmax values of these glutamate subtypes in human brains were about 1/20 of those found in rat brain, although the Kd values were equivalent (5). Moreover, 100 ,uM KA inhibited [3H] glutamate binding by 50% in this experiment and by 18 -30% in the previous reports using the rat brain (11, 12) . These findings suggest a species difference.
The role of excitotoxicity of glutamate in neuronal damages caused by ischemia/ hypoxia now seems to be established. It has been hypothesized that the excitotoxicity of the amino acid may also be involved in the pathogenesis of neurodegenerative diseases of unknown etiology, including Alzheimer's disease. However, there are some discrepancies in the changes in NMDA, QA and KA-sensitive glutamate receptor binding in Alzheimer's disease reported by different laboratories (13) . Although the severity of a disease might determine the degree of receptor changes measured, our present study indicates the importance of the assay and buffer conditions and, we have proposed, an appropriate method to identify possible changes in the glutamate receptor subtypes in Alzheimer postmortem brains.
The most well-characterized class of glutamate receptors is the NMDA receptor (14) , owing in large part to the existence of compounds that specifically block NMDA binding sites (15) . In contrast, elucidation of the non-NMDA receptors, the QA and KA receptors, has been hampered by the lack of such compounds. QA-sensitive [3H] glutamate binding most likely represents binding to the physiologically defined QA receptor on post synaptic neuronal membranes (1, 16) . Therefore, the [3H] glutamate binding site that was displaced by 100 ,u M QA was termed the QA-sensitive binding site in this experiment. It has been reported that the QA inhibition was not specific for the QA subtype of glutamate receptors, and QA binds with high affinity to the QA and KA receptor subtypes and with low affinity to the NMDA subtype (17) (18) (19) . However, it has also been reported that KA and QA bind the same receptor and activate the receptor in cultured neuronal cells (20, 21) . As the detection of glutamate receptor subtypes is controversial, further studies for glutamate receptor subtypes are required. Recently, [3H] aamino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) has been used as a specific radioligand available for quisqualate receptors (22, 23) , and [3H] KA has been used to purify the KA receptors (24, 25) . These [3H] AMPA and [3H] KA might be useful ligands to further clarify the properties of the glutamate receptors in the human brain.
